NEW YORK, Dec. 12, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on BMRN, APVO, OTIC, and EPZM which is a click away at www.wallstequities.com/registration. On Monday, December 11, 2017, US markets saw broad based gains with
On Monday, shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. recorded a trading volume of 4.14 million shares, which was above their three months average volume of 1.25 million shares. The stock ended the session 7.46% higher at $88.11. The Company's shares have gained 6.93% in the last month. The stock is trading above its 50-day moving average by 2.27%. Moreover, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have a Relative Strength Index (RSI) of 61.08. Get started with a complimentary subscription and access to the free report on BMRN at:
Seattle, Washington-based Aptevo Therapeutics Inc.'s stock closed the day 5.67% lower at $3.99 with a total trading volume of 436,758 shares. The Company's shares have advanced 31.25% in the past month, 125.42% in the previous three months, 100.50% over the last twelve months, and 63.52% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 43.19% and 86.36%, respectively. Additionally, shares of Aptevo Therapeutics, which provides oncology and hematology therapeutics, have an RSI of 71.76. Free research on APVO can be accessed at:
Shares in San Diego, California headquartered Otonomy Inc. recorded a trading volume of 505,619 million shares. The stock ended yesterday's trading session 1.98% lower at $4.95. The Company's shares have advanced 41.43% over the previous three months. The stock is trading above its 50-day moving average by 20.72%. Furthermore, shares of Otonomy, which focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the US, have an RSI of 54.14. Sign up today for the free research report on OTIC at:
Cambridge, Massachusetts headquartered Epizyme Inc.'s stock finished Monday's session 3.02% lower at $12.85 with a total trading volume of 410,235 shares. The Company's shares have advanced 15.77% in the past twelve months. The stock is trading below its 50-day moving average by 15.38%. Additionally, shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have an RSI of 43.39. Wall St. Equities' research coverage also includes the downloadable free report on EPZM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACTFor any questions, inquiries, or comments reach out to us directly.If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----biomarin-pharma-aptevo-therapeutics-otonomy-and-epizyme-300570015.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All